Related Experiment Video
Updated: Aug 15, 2026

Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children
Published on: August 22, 2012
Pseudallescheriasis in the 21st century
1The Pennsylvania State University, College of Medicine, Hershey, PA 17033, USA. tobryan@psu.edu
Abstract:
Since its discovery as an agent of mycetoma nearly a century ago, Pseudallescheria boydii with its asexual (synanamorphic) form, Scedosporium apiospermum, is now recognized as an important emerging opportunistic pathogen causing invasive mycosis in immunocompromised patients. The clinical spectrum of pseudallescheriasis is wide. Invasive disease of the lung, CNS and dissemination are serious manifestations in immunocompromised patients. This organism responds poorly to amphotericin B, and its histopathologic resemblance to aspergillosis often results in a delay in diagnosis. In vitro data, animal models and accumulating clinical experience support the use of voriconazole as a primary treatment for pseudallescheriasis. This paper reviews the microbiology, ecology, epidemiologic trends, clinical manifestations and current treatment options of pseudallescheriasis.
Insights
Pseudallescheria boydii (Scedosporium apiospermum) causes invasive infections in immunocompromised patients. Voriconazole shows promise as a primary treatment for this emerging opportunistic pathogen.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Microbiology
Background:
- Pseudallescheria boydii, also known as Scedosporium apiospermum, is an emerging opportunistic pathogen.
- It causes invasive mycosis, particularly in immunocompromised individuals.
- Diagnosis can be delayed due to its resemblance to aspergillosis and poor response to amphotericin B.
Purpose of the Study:
- To review the microbiology, ecology, epidemiology, clinical manifestations, and treatment of pseudallescheriasis.
- To highlight the role of voriconazole in managing infections caused by this fungus.
Main Methods:
- Literature review of published data.
- Analysis of in vitro studies, animal models, and clinical case reports.
Main Results:
- Pseudallescheriasis presents a wide clinical spectrum, including invasive lung and CNS disease.
- The organism exhibits resistance to amphotericin B.
- Voriconazole demonstrates efficacy in vitro, in animal models, and in clinical settings.
Conclusions:
- Pseudallescheria boydii (Scedosporium apiospermum) is a significant cause of invasive fungal infections.
- Voriconazole is a recommended primary treatment option for pseudallescheriasis.
- Further research is needed to fully understand and manage this emerging pathogen.
Related Concept Videos
Giardiasis
Leishmaniasis
American Trypanosomiasis
Fungal Phylum Microsporidia
Amebiasis
Diversity of Protists II